NEW YORK (GenomeWeb News) – TB Biosciences, which is developing a point-of-care test for the detection of tuberculosis, said today it has closed on its Series A financing round, raising $1.5 million.

The financing will be used to support product development and clinical trials.

Originate Ventures led the round, which also included investors Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund. With recent funding from the National Institutes of Health, new funds total $2.5 million, the Bethlehem, Penn.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.